Safety Profile

A tolerability profile in clinical trials with children and adults with EPI due to CF1

Treatment-emergent adverse events (AEs) occurring in at least 2 ZENPEP-treated patients (Study 1)1

This table depicts treatment-emergent AEs in patients with EPI due to CF aged ≥7 years that occurred in at least 2 patients (≥6%) during treament and crossover treatment periods with ZENPEP in Study 1.1

  • In the randomized trial (ZENPEP Study 1), the most common AEs (≥6% of patients treated with ZENPEP) were abdominal pain, flatulence, headache, contusion, decreased weight, cough, and early satiety1
  • No patient discontinued ZENPEP due to an AE or laboratory abnormality in the clinical trials2
  • No drug-related serious AEs were observed in the clinical trials2

Dosing

Additional ZENPEP® Support

Request Patient Support Resources

Calculate the ZENPEP Dose in 3 Easy Steps!

Discover the Two Key Goals for Managing EPI